Drug Monograph
Carvedilol
Coreg, Coreg CR
Pharmacokinetic Profile
Half-Life
6–10 h
Metabolism
Hepatic (CYP2D6, CYP2C9)
Protein Binding
>98%
Bioavailability
25–35% (oral)
Volume of Distribution
~115 L (~1.5 L/kg)
Clinical Information
Drug Class
Non-selective beta-blocker + alpha-1 blocker
Available Doses
IR: 3.125, 6.25, 12.5, 25 mg tabs; CR: 10, 20, 40, 80 mg caps
Route
Oral only
Renal Adjustment
Not required
Hepatic Adjustment
Contraindicated in severe impairment
Pregnancy
Risk cannot be ruled out; neonatal risk
Lactation
Not recommended
Schedule / Legal Status
Rx only (not scheduled)
Generic Available
Yes
Approved Indications & Off-Label Uses
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Chronic heart failure (mild-to-severe, HFrEF) | Adults | Adjunctive to diuretics, ACEi, digitalis | FDA Approved |
| LV dysfunction post-MI (LVEF ≤40%) | Adults (clinically stable) | Adjunctive | FDA Approved |
| Essential hypertension | Adults | Monotherapy or combination | FDA Approved |
Carvedilol occupies a unique position among beta-blockers as a non-selective agent with additional alpha-1 adrenergic blockade, conferring vasodilatory properties not shared by most other beta-blockers. It is one of only three beta-blockers (alongside bisoprolol and metoprolol succinate) recommended by the 2022 AHA/ACC/HFSA guidelines for mortality reduction in heart failure with reduced ejection fraction. The landmark COPERNICUS, US Carvedilol Heart Failure trials, and CAPRICORN trial established its role in mild-to-severe HFrEF and post-MI LV dysfunction.
Off-Label Uses
Portal hypertension / variceal bleeding prophylaxis — Carvedilol reduces hepatic venous pressure gradient more effectively than propranolol in some studies; supported by ESGE guidelines for primary prophylaxis in cirrhotic patients. Evidence quality: High.
Atrial fibrillation rate control — Used for ventricular rate control, particularly when concurrent heart failure is present. Evidence quality: Moderate.
Stable angina pectoris — Beta-blocking activity reduces myocardial oxygen demand; alpha-1 blockade provides coronary vasodilation. Evidence quality: Moderate.
Ventricular arrhythmias — Non-selective beta-blockade may suppress ventricular ectopy in select patients. Evidence quality: Low.
Dosing by Clinical Scenario
Adult Dosing — Immediate-Release Tablets
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Heart failure (HFrEF) — mild to moderate | 3.125 mg BID | Titrate: 6.25 → 12.5 → 25 mg BID | <85 kg: 25 mg BID; ≥85 kg: 50 mg BID | Take with food; titrate at ≥2-week intervals; minimize fluid retention before starting Reduce dose if HR <55 bpm; physician must closely monitor during up-titration |
| Heart failure (HFrEF) — severe (NYHA IV) | 3.125 mg BID | Titrate cautiously q2wk | 25 mg BID | Patient must be clinically euvolemic; increase diuretics for fluid retention episodes Based on COPERNICUS trial protocol |
| Post-MI LV dysfunction (LVEF ≤40%) | 6.25 mg BID | Titrate: 12.5 → 25 mg BID | 25 mg BID | Start when hemodynamically stable; titrate every 3–10 days based on tolerability May start at 3.125 mg BID if clinically indicated (low BP or HR) |
| Essential hypertension | 6.25 mg BID | Titrate: 12.5 → 25 mg BID | 25 mg BID (50 mg/day) | Titrate every 7–14 days; assess standing SBP 1 hour post-dose for tolerance Full antihypertensive effect evident within 7–14 days of each dose level |
| Portal hypertension — variceal prophylaxis (off-label) | 6.25 mg once daily | Titrate to 12.5 mg once daily | 12.5 mg once daily | Contraindicated in severe or refractory ascites; lower doses than cardiovascular indications Monitor for systemic hypotension; per ESGE guidance |
Special Populations
| Population | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Elderly (≥65 years) | 3.125 mg BID | Titrate cautiously | Standard adult max | Plasma levels ~50% higher in elderly; greater risk of hypotension and syncope during up-titration |
| Hepatic impairment (mild-moderate) | Standard | Standard | Standard | No dose adjustment typically needed for mild-moderate impairment |
| Hepatic impairment (severe) | Contraindicated. Carvedilol plasma levels increase 4–7-fold in severe hepatic impairment (cirrhosis). Do not use. | |||
| Renal impairment | No dose adjustment required. High protein binding (>98%) means carvedilol is not significantly removed by hemodialysis. | |||
Clinical Pearl: IR to CR Conversion
Patients stable on immediate-release carvedilol can be switched to Coreg CR (extended-release capsules) at equivalent total daily doses: IR 3.125 mg BID = CR 10 mg daily; IR 6.25 mg BID = CR 20 mg daily; IR 12.5 mg BID = CR 40 mg daily; IR 25 mg BID = CR 80 mg daily. The CR capsules must be taken once daily in the morning with food and swallowed whole (not crushed or chewed). For elderly patients switching from higher IR doses, consider starting at a lower CR dose to reduce syncope risk.
Pharmacology
Mechanism of Action
Carvedilol is a racemic mixture that delivers a dual pharmacologic profile distinguishing it from conventional beta-blockers. The S(-) enantiomer provides non-selective beta-adrenergic blockade (both beta-1 and beta-2), while both the R(+) and S(-) enantiomers contribute alpha-1 adrenergic blocking activity. This alpha-1 antagonism results in peripheral vasodilation and reduced systemic vascular resistance, which offsets the potential for initial worsening of cardiac output typically seen with pure beta-blockers in heart failure. Carvedilol also possesses antioxidant properties, scavenging oxygen free radicals and inhibiting lipid peroxidation in cardiac membranes. It has no intrinsic sympathomimetic activity. In heart failure, carvedilol reduces cardiac workload through afterload reduction (alpha-1 block) and heart rate reduction (beta block), while protecting the myocardium from catecholamine-mediated toxicity over time.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapid; Tmax 1–2 h (IR), ~5 h (CR); bioavailability 25–35% due to extensive first-pass metabolism | Take with food to slow absorption and reduce orthostatic hypotension risk; food does not reduce total bioavailability |
| Distribution | Vd ~115 L (~1.5 L/kg); protein binding >98% (albumin); highly lipophilic; crosses blood-brain barrier | Very high protein binding limits hemodialysis clearance; extensive tissue distribution contributes to sustained beta-blockade |
| Metabolism | Hepatic via CYP2D6, CYP2C9 (primary); also CYP3A4, CYP1A2, CYP2E1; aromatic ring oxidation and glucuronidation; 3 active metabolites (weak activity); also a P-glycoprotein inhibitor | CYP2D6 poor metabolizers (~7% of population) show 2–3-fold higher R(+)-carvedilol levels, but clinical impact is limited because carvedilol is titrated to effect; P-gp inhibition underlies cyclosporine and digoxin interactions |
| Elimination | t½ 6–10 h; R(+) 5–9 h, S(-) 7–11 h; primarily via bile/feces; <2% unchanged in urine; 16% total urinary excretion | Predominantly hepatic elimination; no renal dose adjustment needed; severe hepatic impairment increases levels 4–7-fold (contraindicated) |
Carvedilol Side Effects
≥10%
Very Common (Heart Failure Trials)
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Dizziness | 24–32% | Most common complaint; dose-related (increases from 2% to 5% in hypertension as dose rises from 6.25 to 50 mg/day); largely due to alpha-1-mediated vasodilation; worse during up-titration |
| Fatigue | 24% | Similar to placebo rate in mild-moderate HF trials (22% placebo); distinguish from disease-related fatigue; may improve as cardiac output improves over weeks |
| Hypotension | 9–14% | Alpha-1 blockade-related; highest risk during first 30 days (up-titration period); taking with food and separating from ACEi dosing reduces risk |
| Diarrhea | 12% | More common than placebo (6%); usually self-limiting; maintain hydration |
| Hyperglycemia | 12% | More common than placebo (8%); monitor glucose in diabetic patients; may worsen glycemic control in HF patients |
| Asthenia | 7–11% | Generalized weakness; more notable in severe HF (COPERNICUS); usually improves as cardiac function stabilizes |
| Weight increase | ~10% | Likely reflects fluid retention rather than adipose gain; monitor daily weight; increase diuretics if weight gain >1–2 kg over a few days |
1–10%
Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Bradycardia | 2–10% | 2% in hypertension, 9% in mild-moderate HF, 10% in severe HF (COPERNICUS); reduce dose if HR <55 bpm |
| Nausea / vomiting | 4–9% | Taking with food mitigates GI symptoms; reassess if persistent |
| Headache | 5–8% | May be related to vasodilation; usually transient during dose adjustment |
| Edema (generalized/dependent) | 4–6% | Distinguish from worsening HF; increase diuretics as needed; peripheral edema more common than generalized |
| Syncope | 3–8% | 3% in mild-moderate HF (vs 3% placebo), 8% in severe HF/COPERNICUS (vs 5% placebo); highest risk during initiation and up-titration; warn patients about driving and hazardous tasks |
| Postural hypotension | 1.8–2% | Alpha-1 blockade-mediated; counsel patients to rise slowly; more frequent in hypertension trials during initial dosing |
| Visual disturbances / blurred vision | 1–5% | May relate to reduced tear production; inform ophthalmologist about alpha-blocker use before cataract surgery (IFIS risk) |
| Insomnia | 1–2% | Lipophilic agent crosses blood-brain barrier; consider AM dosing if sleep is disturbed |
Serious
Serious (Regardless of Frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Worsening heart failure | Common during up-titration | First 1–3 months | Increase diuretics; do not advance carvedilol dose until stable; may need temporary dose reduction |
| Severe bradycardia (HR <50 bpm) | 2–10% | Days to weeks after initiation | Reduce dose; atropine 2 mg IV for symptomatic bradycardia; glucagon for refractory cases |
| Severe hypotension / cardiogenic shock | Uncommon | First dose or dose increase | Trendelenburg; IV fluids; vasopressors if needed; hold carvedilol until stable |
| Bronchospasm / status asthmaticus | Rare (deaths reported) | Any time; can occur after single dose | Contraindicated in asthma; beta-2 agonist bronchodilator; emergency care; permanent discontinuation |
| AV block (2nd/3rd degree) | 1–3% | Days to weeks | Discontinue carvedilol; atropine or isoproterenol; evaluate for pacing |
| Hepatic injury | Rare | Weeks to months | Check LFTs; discontinue if transaminases rise >3x ULN; reversible upon drug withdrawal |
| Rebound angina/MI on abrupt withdrawal | Rare (if tapered properly) | 1–7 days post-discontinuation | Taper over 1–2 weeks; reinstate promptly if rebound symptoms occur |
| Stevens-Johnson syndrome / TEN | Very rare (postmarketing) | Variable | Immediate discontinuation; dermatology/burn center referral; supportive care |
Discontinuation
Discontinuation Data
Heart Failure Trials (mild-moderate)
Similar to placebo
Top reasons: Dizziness (1.3% carvedilol vs 0.6% placebo in COPERNICUS), worsening HF, hypotension
Hypertension Trials
4.9% vs 5.2% placebo
Top reasons: Postural hypotension (1% vs 0%), dizziness
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Hypotension | 1.5% (CAPRICORN) | Most common single cause in post-MI trial (vs 0.2% placebo) |
| Dizziness | 1.3% (COPERNICUS) | vs 0.6% placebo; only individual cause of discontinuation >1% in severe HF trial |
| Postural hypotension | 1% (HTN trials) | vs 0% placebo; dose-related; most events during initial titration |
| Worsening heart failure | <1% | Usually manageable with diuretic adjustment; does not preclude future retitration |
Managing Dizziness and Hypotension — The Most Impactful Side Effects
Dizziness and hypotension are driven by alpha-1 blockade and are most pronounced during up-titration. Three key strategies reduce their impact: (1) always administer carvedilol with food, (2) separate the timing of carvedilol from ACE inhibitor dosing, and (3) consider temporarily reducing the ACE inhibitor dose if vasodilatory symptoms persist. Patients should avoid driving or hazardous activities for the first hour after each new dose level. These symptoms typically diminish as hemodynamic compensation occurs over days to weeks.
Drug Interactions
Carvedilol is metabolized by CYP2D6 and CYP2C9 with lesser contributions from CYP3A4, CYP1A2, and CYP2E1. It is also a P-glycoprotein (P-gp) inhibitor, which underlies its interactions with cyclosporine and digoxin. The most clinically significant interactions involve CYP2D6 inhibitors, drugs that slow AV conduction, and agents with additive hypotensive effects.
MajorVerapamil / Diltiazem
MechanismAdditive negative chronotropy, dromotropy, and inotropy
EffectSevere bradycardia, AV block, hypotension, and heart failure
ManagementMonitor ECG and blood pressure closely if oral co-use is essential; avoid IV co-administration
FDA PIMajorClonidine (on withdrawal)
MechanismUnopposed alpha stimulation when clonidine is withdrawn while beta-blocker continues
EffectSevere rebound hypertension
ManagementStop carvedilol several days before tapering clonidine; close BP monitoring
FDA PIMajorAmiodarone
MechanismCYP2C9 inhibition increases carvedilol levels; additive AV conduction slowing
EffectEnhanced bradycardia, hypotension, and cardiac conduction abnormalities
ManagementMonitor HR and ECG closely; may need carvedilol dose reduction
FDA PIModerateFluoxetine / Paroxetine
MechanismPotent CYP2D6 inhibition increases carvedilol levels, particularly R(+) enantiomer
EffectEnhanced hypotension and bradycardia; increased fall risk
ManagementMonitor HR/BP; prefer SSRIs with minimal CYP2D6 inhibition (e.g., sertraline, citalopram)
FDA PI / LexicompModerateCyclosporine
MechanismCarvedilol inhibits P-glycoprotein-mediated transport, increasing cyclosporine exposure
EffectIncreased cyclosporine blood concentrations and nephrotoxicity risk
ManagementMonitor cyclosporine trough levels closely; reduce cyclosporine dose as needed
FDA PIModerateDigoxin
MechanismAdditive AV conduction slowing; carvedilol increases digoxin AUC by ~14% and trough by ~16%
EffectIncreased risk of bradycardia and digoxin toxicity
ManagementMonitor digoxin levels and heart rate at initiation and dose changes
FDA PIModerateInsulin / Oral hypoglycemics
MechanismBeta-blockade masks hypoglycemic symptoms; carvedilol may worsen hyperglycemia in HF patients
EffectDelayed recognition of hypoglycemia; possible worsening of glycemic control
ManagementMonitor blood glucose more frequently; educate patients on non-adrenergic hypoglycemia signs
FDA PIMinorRifampin
MechanismPotent hepatic enzyme induction decreases carvedilol AUC and Cmax by ~70%
EffectSubstantially reduced carvedilol efficacy
ManagementMonitor BP and HR; significantly higher carvedilol doses may be needed; consider alternative beta-blocker
FDA PIMinorCimetidine
MechanismNon-specific CYP inhibition increases carvedilol steady-state AUC by ~30%
EffectMild increase in carvedilol exposure; no change in Cmax
ManagementUsually not clinically significant; monitor if symptomatic
FDA PIMonitoring Parameters
- Heart RateEvery visit; within 1 h of each dose increase
RoutineReduce carvedilol dose if HR drops below 55 bpm. During up-titration in HF, observe for at least 1 hour after the first dose and after each increase. - Blood PressureEvery visit; standing BP 1 h post-dose
RoutineMeasure standing SBP 1 hour after dosing to assess tolerance, especially during titration. Orthostatic drop >20 mmHg warrants dose adjustment. - Body WeightDaily (patient self-monitoring)
RoutineInstruct HF patients to weigh themselves daily. Gain of >1–2 kg over a few days suggests fluid retention; increase diuretics before advancing carvedilol. - Signs of Heart FailureEach visit during titration
Trigger-basedAssess for dyspnea, edema, JVP elevation. Worsening during first 3 months may occur but resolves with diuretic adjustment; does not preclude successful long-term treatment. - Blood GlucoseAt initiation, dose changes, and periodically
RoutineCarvedilol may worsen hyperglycemia in HF patients and mask hypoglycemic symptoms. Monitor glucose closely when initiating, adjusting, or discontinuing carvedilol. - Renal FunctionBaseline; during up-titration in at-risk patients
Trigger-basedDeterioration of renal function has rarely occurred in HF patients, particularly those with low BP, ischemic heart disease, or underlying renal insufficiency. Discontinue or reduce dose if worsening occurs. - Hepatic FunctionBaseline; if hepatotoxicity suspected
Trigger-basedRare hepatic injury reported; check LFTs if jaundice or symptoms of liver dysfunction develop. Discontinue if confirmed.
Contraindications & Cautions
Absolute Contraindications
- Bronchial asthma or related bronchospastic conditions — deaths from status asthmaticus have been reported following single doses of carvedilol
- Second- or third-degree AV block (without a pacemaker)
- Sick sinus syndrome (without a pacemaker)
- Severe bradycardia (unless a permanent pacemaker is in place)
- Cardiogenic shock or decompensated heart failure requiring IV inotropic therapy
- Severe hepatic impairment — carvedilol levels increase 4–7-fold
- Serious hypersensitivity to carvedilol or its components (SJS, anaphylaxis, angioedema)
Relative Contraindications (Specialist Input Recommended)
- Pheochromocytoma — despite dual alpha/beta activity, an alpha-blocker should be established first; limited clinical experience with carvedilol in this setting
- Prinzmetal (variant) angina — non-selective beta-blockade may provoke vasospasm, although alpha-1 blocking activity may offer some protection
- Severe or refractory ascites (in portal hypertension context) — increased risk of systemic hypotension
Use with Caution
- Diabetes mellitus — may mask hypoglycemic symptoms; may worsen hyperglycemia in HF patients
- Non-allergic bronchospasm (COPD, emphysema) — use lowest effective dose; have beta-2 agonist available
- Peripheral vascular disease — may aggravate symptoms of arterial insufficiency
- Thyrotoxicosis — may mask tachycardia; abrupt withdrawal may precipitate thyroid storm
- Major surgery — do not routinely withdraw chronic beta-blocker therapy preoperatively
- Cataract surgery — risk of intraoperative floppy iris syndrome (IFIS) due to alpha-1 blockade; alert the ophthalmologist
- Elderly — plasma levels ~50% higher; increased syncope risk during conversion from IR to CR
FDA Class-Wide Regulatory Warning
Abrupt Cessation of Beta-Blocker Therapy
Patients with coronary artery disease should not abruptly discontinue carvedilol. Severe exacerbation of angina, myocardial infarction, and ventricular arrhythmias have been reported following sudden withdrawal. When discontinuation is planned, taper the dose over 1 to 2 weeks with close monitoring. If angina worsens or acute coronary insufficiency develops, reinstate carvedilol promptly. Even patients treated solely for hypertension or heart failure should not stop abruptly, as unrecognized coronary artery disease is common.
Patient Counselling
Purpose of Therapy
Carvedilol helps your heart work more efficiently by lowering heart rate, reducing blood pressure, and relaxing blood vessels. Depending on your condition, it may be used to treat heart failure, protect your heart after a heart attack, or manage high blood pressure. While you may feel worse during the first few weeks as the dose is gradually increased, clinical studies show that long-term use significantly improves heart function and survival.
How to Take
Always take carvedilol with food — this reduces the risk of dizziness and lightheadedness. Take it at the same times each day, usually twice daily for the immediate-release tablets or once daily in the morning for the extended-release capsules. Swallow the extended-release capsules whole; do not crush or chew them. Your doctor will start you on a low dose and gradually increase it over several weeks. Do not stop taking this medication suddenly.
Dizziness & Lightheadedness
Tell patientDizziness is the most common side effect, especially when your dose is being increased. It often occurs within the first hour after a dose. Rise slowly from sitting or lying positions. Avoid driving or hazardous tasks after your first dose or a dose increase until you know how you respond.
Call prescriberIf dizziness is severe, causes falls, or is accompanied by fainting.
Weight Monitoring (Heart Failure Patients)
Tell patientWeigh yourself every morning at the same time, after using the bathroom but before eating. Record your weight. Contact your prescriber immediately if you gain more than 1–2 kg (2–3 lb) in a few days, as this may indicate fluid retention that needs treatment.
Call prescriberIf you notice rapid weight gain, increased swelling in ankles/legs, or increasing shortness of breath.
Never Stop Suddenly
Tell patientStopping carvedilol suddenly can cause dangerous effects including worsening chest pain, heart attack, or severely elevated blood pressure. Always contact your doctor before making any changes. If you run out of medication, seek a refill immediately.
Call prescriberIf you have missed several doses, or if you develop chest pain or rapid heartbeat after missing doses.
Blood Sugar (Diabetic Patients)
Tell patientThis medication may mask some warning signs of low blood sugar (such as rapid heartbeat) and may also raise your blood sugar levels. Check your blood sugar more frequently when starting carvedilol or changing the dose. Sweating and hunger remain as warning signs of low blood sugar.
Call prescriberIf your blood sugar becomes harder to control, or if you experience frequent episodes of low blood sugar.
Eye Surgery
Tell patientIf you need cataract surgery, inform your eye surgeon that you are taking carvedilol. This medication can cause a condition called intraoperative floppy iris syndrome (IFIS) that your surgeon needs to prepare for. Stopping the medication before surgery does not appear to help.
Call prescriberBefore any scheduled eye surgery to discuss your medications.
Feeling Worse Before Better (Heart Failure)
Tell patientDuring the first weeks of treatment, you may feel more tired or notice increased shortness of breath or swelling. This is a temporary effect as your body adjusts. Clinical studies show that patients who continue through this period experience significant long-term improvements in heart function and survival.
Call prescriberIf worsening symptoms are severe, do not improve within a few days, or you need to sleep propped up on extra pillows to breathe.
Sources
Regulatory (PI / SmPC)
- COREG (carvedilol) tablets for oral use — FDA-approved prescribing information (revised July 2023). accessdata.fda.govPrimary regulatory source for all approved indications, dosing, contraindications, adverse reaction incidence data, and pharmacokinetics of the immediate-release formulation.
- COREG CR (carvedilol phosphate) extended-release capsules — FDA prescribing information (2015). accessdata.fda.govCross-reference for IR-to-CR dose conversion, extended-release pharmacokinetics, and bioequivalence data.
Key Clinical Trials
- Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334(21):1349–1355. doi:10.1056/NEJM199605233342101US Carvedilol Heart Failure Study Group trial demonstrating 65% reduction in mortality risk in mild-to-moderate HFrEF (n=1,094); led to FDA approval for heart failure.
- Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–1658. doi:10.1056/NEJM200105313442201COPERNICUS trial showing 35% mortality reduction in severe HFrEF (NYHA III–IV, LVEF <25%); stopped early for benefit (n=2,289).
- The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction. Lancet. 2001;357(9266):1385–1390. doi:10.1016/S0140-6736(00)04560-8Demonstrated reduced cardiovascular mortality in post-MI patients with LVEF ≤40% (n=1,959); basis for the post-MI LV dysfunction indication.
- Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the COMET trial. Lancet. 2003;362(9377):7–13. doi:10.1016/S0140-6736(03)13800-7Head-to-head trial showing carvedilol superiority over metoprolol tartrate on all-cause mortality in chronic HF (n=3,029); though metoprolol tartrate dosing adequacy was debated.
Guidelines
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17):e263–e421. doi:10.1016/j.jacc.2021.12.012Current US guideline recommending carvedilol, bisoprolol, or metoprolol succinate as the 3 evidence-based beta-blockers for HFrEF to reduce mortality and hospitalizations.
- de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII — Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–974. doi:10.1016/j.jhep.2021.12.022Consensus guidelines supporting carvedilol as an alternative to propranolol for primary prophylaxis of variceal bleeding in cirrhotic patients with portal hypertension.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA Guideline for the Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018;71(19):e127–e248. doi:10.1016/j.jacc.2017.11.006US hypertension guideline; beta-blockers not first-line for uncomplicated hypertension but indicated with compelling indications (HFrEF, post-MI).
Mechanistic / Basic Science
- Feuerstein GZ, Ruffolo RR Jr. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J. 1995;16(Suppl F):38–42. doi:10.1093/eurheartj/16.suppl_f.38Foundational review of carvedilol’s unique triple mechanism: non-selective beta-blockade, alpha-1 blockade, and antioxidant free radical scavenging activity.
Pharmacokinetics / Special Populations
- Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet. 1994;26(5):335–346. doi:10.2165/00003088-199426050-00002Comprehensive PK review establishing bioavailability (25–35%), protein binding (>98%), hepatic first-pass metabolism, and enantiomer-specific half-lives.
- Gehr TWB, Tenero DM, Boyle DA, et al. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol. 1999;55(4):269–277. doi:10.1007/s002280050628PK study demonstrating 40–50% higher plasma levels in patients with moderate-severe renal impairment, though no dose adjustment is recommended due to titration-to-effect approach.
- Packer M, Lukas MA, Tenero DM, Baidoo CA, Greenberg BH. Pharmacokinetic profile of controlled-release carvedilol in patients with LV dysfunction. Am J Cardiol. 2006;98(7A):39L–45L. doi:10.1016/j.amjcard.2006.07.016Established bioequivalence of COREG CR and immediate-release carvedilol at corresponding doses in heart failure patients.